Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta; Yaneicy Gonzalez-Rojas; Erick Juarez; Manuel Crespo Casal; Jaynier Moya; Diego R Falci; Élias Sarkis; Joel Solis; Hanzhe Zheng; Nicola Scott; Andrea L. Cathcart; Christy M. Hebner; Jennifer Sager; Erik Mogalian; Craig Tipple; Amanda Peppercorn; Elizabeth Alexander; Pang Phillip S; Almena Free; Cynthia Brinson; Melissa Aldinger; Adrienne E. Shapiro

doi:10.1056/nejmoa2107934

Abstract

Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.).

Affiliated Institutions

Services Hospital PK

Related Publications

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Mazin Abdelghany , Santosh Davies , Nicole Behenna-Renton +27 more

Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of...

2021 New England Journal of Medicine 1224 citations

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen , Ajay Nirula , Barry N. Heller +19 more

In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas th...

2020 New England Journal of Medicine 1412 citations

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama , Jian Han , Linda Yau +17 more

In hospitalized patients with Covid-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mec...

2020 New England Journal of Medicine 1297 citations

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Angélica Jayk Bernal , Monica Maria Gomes da Silva , Dany Badibanga Musungaie +19 more

Early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19. (Funded by Merck Sharp and Dohme; MOVe-OUT Clinical...

2021 New England Journal of Medicine 1826 citations

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

David M. Weinreich , Sumathi Sivapalasingam , Thomas Norton +30 more

In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a hig...

2020 New England Journal of Medicine 1763 citations

Publication Info

Year: 2021
Type: article
Volume: 385
Issue: 21
Pages: 1941-1950
Citations: 1053
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1053

OpenAlex

Cite This

APA Style

                            
                                
                                    Anil Gupta, 
                                
                                    Yaneicy Gonzalez-Rojas, 
                                
                                    Erick Juarez
                                
                                et al.
                            
                            (2021). 
                            Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. 
                            New England Journal of Medicine
                            , 385
                            (21)
                            , 1941-1950.
                            https://doi.org/10.1056/nejmoa2107934
                        

Identifiers

DOI: 10.1056/nejmoa2107934